Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 4168 results found since Jan 2013.

Advances in the research and development of natural health products as main stream cancer therapeutics.
Authors: Ovadje P, Roma A, Steckle M, Nicoletti L, Arnason JT, Pandey S Abstract Natural health products (NHPs) are defined as natural extracts containing polychemical mixtures; they play a leading role in the discovery and development of drugs, for disease treatment. More than 50% of current cancer therapeutics are derived from natural sources. However, the efficacy of natural extracts in treating cancer has not been explored extensively. Scientific research into the validity and mechanism of action of these products is needed to develop NHPs as main stream cancer therapy. The preclinical and clinical validation o...
Source: Evidence-based Complementary and Alternative Medicine - June 3, 2015 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients - A pragmatic randomized controlled trial.
CONCLUSION: Results suggest that the global health status and subjective wellbeing of cancer patients improve significantly when adjunct classical homeopathic treatment is administered in addition to conventional therapy. PMID: 26051564 [PubMed - in process]
Source: Complementary Therapies in Medicine - June 1, 2015 Category: Complementary Medicine Authors: Frass M, Friehs H, Thallinger C, Sohal NK, Marosi C, Muchitsch I, Gaertner K, Gleiss A, Schuster E, Oberbaum M Tags: Complement Ther Med Source Type: research

Personalized Medicine in Radiation Oncology—A Work in Progress
Personalized medicine holds immense promise in cancer care. With increasing understanding of the complexity of tumor heterogeneity, we are realizing that one size does not fit all, and perhaps, cancer therapy should be tailored to patients and their individualized tumor molecular signatures. Within medical oncology the search for personalized medicine has yielded numerous targeted agents. Novel medications have demonstrated significant activity within subsets of tumors which harbor specific targetable mutations.
Source: International Journal of Radiation Oncology * Biology * Physics - June 19, 2015 Category: Radiology Authors: Christopher J. Anker, Jennifer Y. Wo Tags: Commentary Source Type: research

Predictive biomarkers in precision medicine and drug development against lung cancer.
Authors: Fang B, Mehran RJ, Heymach JV, Swisher SG Abstract The molecular characterization of various cancers has shown that cancers with the same origins, histopathologic diagnoses, and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause tumorigenesis. A number of cancer driver genes with functional abnormalities that trigger malignant transformation and that are required for the survival of cancer cells have been identified. Therapeutic agents targeting some of these cancer drivers have been successfully developed, resulting in substantial improvements in clinical sy...
Source: Chinese Journal of Cancer - July 5, 2015 Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research

Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine.
Abstract Gastric cancer imposes a global health burden. Although multimodal therapies have proven to benefit patients with advanced diseases after curative surgery, the prognosis of most advanced cancer patients still needs to be improved. Surgical extirpation is the mainstay of gastric cancer treatment. Indeed, without curative surgery, variations and combinations of chemotherapy and/or radiation cannot bring clinically meaningful success. Centered around D2 surgery, adjuvant and peri-operative multimodal therapies have improved survival in a certain group of gastric cancer patients. Moving toward a personalized ...
Source: Yonsei Medical Journal - August 13, 2015 Category: Universities & Medical Training Authors: Choi YY, Noh SH, Cheong JH Tags: Yonsei Med J Source Type: research

YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells
Conclusion: YZXJ has a significant role in reducing the migration, invasion and in vivo tumour growth of lung cancer and acts to inhibit the migratory and invasive effects induced by HGF and indeed by HGF/EGF. This effect is likely attributed to the inhibition of the HGF receptor activation. These results indicate that YZXJ has a therapeutic role in lung cancer and that combined strategy with methods to block HGF and EGF should be considered.
Source: Journal of Translational Medicine - August 27, 2015 Category: Research Authors: Wen JiangLin YeFiona RugeSioned OwenTracey MartinPing-Hui SunAndrew SandersJane LaneLucy SatherleyHoi WeeksYong GaoCong WeiYiling WuMalcolm Mason Source Type: research

Translating predictive biomarkers within oncology clinical development programs.
Authors: Beckman RA, Chen C Abstract Predictive biomarkers provide essential information to enable personalized medicine, and hold the promise for enhancing the effectiveness and value of cancer therapies. However, they do not always work. This review provides a framework for managing the risk of predictive biomarkers and maximally harvesting their benefit. Methods are provided which permit data-driven, adaptive decision making about the use of predictive biomarkers during clinical development, applying them to the extent they are validated by the clinical data. Techniques for optimizing overall development efficie...
Source: Future Medicine: Biomarkers in Medicine - September 22, 2015 Category: Internal Medicine Tags: Biomark Med Source Type: research

Cell-free DNA as a novel marker in cancer therapy.
Authors: Kato S, Janku F Abstract Advances in next-generation sequencing have provided new insights and new therapeutic options for patients with cancer. However, assessment of genomic aberrations, which is required for precision medicine, has been challenging because of the difficulties in capturing intratumoral heterogeneity and in real-time assessment of tumors. Recent advances in technology have enabled detection and analysis of cell-free DNA in cancer patients, which provides real-time assessment of tumor evolution. Here, we review the recent advances in our understanding of the clinical utility of cell-free D...
Source: Future Medicine: Biomarkers in Medicine - September 22, 2015 Category: Internal Medicine Tags: Biomark Med Source Type: research

Cancer immunotherapy in veterinary medicine: current options and new developments
Publication date: Available online 13 October 2015 Source:The Veterinary Journal Author(s): Daniel Regan, Amanda Guth, Jonathan Coy, Steven Dow Excitement in the field of tumor immunotherapy is being driven by several remarkable breakthroughs in recent years. This review will cover recent advances in cancer immunotherapy, including the use of T cell checkpoint inhibitors, engineered T cells, cancer vaccines, and anti-B cell and T cell antibodies. Inhibition of T cell checkpoint molecules such as PD-1 and CTLA-4 using monoclonal antibodies has achieved notable success against advanced tumors in humans, including melan...
Source: The Veterinary Journal - October 20, 2015 Category: Veterinary Research Source Type: research

Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine.
Authors: DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE Abstract Research models that replicate the diverse genetic and molecular landscape of breast cancer are critical for developing the next-generation therapeutic entities that can target specific cancer subtypes. Patient-derived tumorgrafts, generated by transplanting primary human tumor samples into immune-compromised mice, are a valuable method to model the clinical diversity of breast cancer in mice, and are a potential resource in personalized medicine. Primary tumorgrafts also enable in vivo testing of therapeutics and ...
Source: Current Protocols in Pharmacology - November 18, 2015 Category: Drugs & Pharmacology Tags: Curr Protoc Pharmacol Source Type: research

ECM and ECM-like materials - Biomaterials for applications in regenerative medicine and cancer therapy.
Abstract Regenerative strategies, such as stem cell-based therapies and tissue engineering applications, are being developed with the aim to replace, remodel, regenerate or support damaged tissues and organs. In addition to careful cell type selection, the design of appropriate three-dimensional (3D) scaffolds is essential for the generation of bio-inspired replacement tissues. Such scaffolds are usually made of degradable or non-degradable biomaterials and can serve as cell or drug carriers. The development of more effective and efficient drug carrier systems is also highly relevant for novel cancer treatment str...
Source: Advanced Drug Delivery Reviews - December 3, 2015 Category: Drugs & Pharmacology Authors: Hinderer S, Layland SL, Schenke-Layland K Tags: Adv Drug Deliv Rev Source Type: research

Traditional Chinese medicine targeting apoptotic mechanisms for esophageal cancer therapy.
Abstract Esophageal cancer is one of the most common types of cancer in the world, and it demonstrates a distinct geographical distribution pattern in China. In the last decade, inducing apoptosis with traditional Chinese medicine (TCM) has become an active area in both fundamental and clinical research on cancer therapy. In this review, we summarize the molecular mechanisms by which TCM induces apoptosis in esophageal cancer cells. These mechanisms are generally related but not limited to targeting the extrinsic death receptor pathway, the intrinsic mitochondrial pathway, and the endoplasmic reticulum (ER) stress...
Source: Acta Pharmacologica Sinica - December 28, 2015 Category: Drugs & Pharmacology Authors: Zhang YS, Shen Q, Li J Tags: Acta Pharmacol Sin Source Type: research

Pituitary Medicine From Discovery to Patient-Focused Outcomes.
CONCLUSIONS: Novel diagnostic techniques including imaging genomic, proteomic, and biochemical analyses will yield further knowledge to enable diagnosis of heretofore cryptic syndromes, as well as sub classifications of pituitary syndromes for personalized treatment approaches. Cost effective personalized approaches to precision therapy must demonstrate value, and will be empowered by multidisciplinary approaches to integrating complex subcellular information to identify therapeutic targets for enabling maximal outcomes. These goals will be challenging to attain given the rarity of pituitary disorders and the difficulty in...
Source: The Journal of Clinical Endocrinology and Metabolism - February 23, 2016 Category: Endocrinology Authors: Melmed S Tags: J Clin Endocrinol Metab Source Type: research

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome.
Abstract This perspective describes the motivation, development, and implementation of pathway-based content for My Cancer Genome, an online precision medicine knowledge resource describing clinical implications of genetic alterations in cancer. As researchers uncover more about cancer pathogenesis, we are learning more not only about the specific genes and proteins involved but also about how those genes and proteins interact with others along cell signaling pathways. This knowledge has led researchers and clinicians to begin to think about cancer therapy using a pathway-based approach. To facilitate this approac...
Source: Translational Oncology - March 31, 2016 Category: Cancer & Oncology Authors: Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM Tags: Transl Oncol Source Type: research

Current Usage of Traditional Chinese Medicine in the Management of Breast Cancer: A Practitioners Perspective
Conclusion. The lack of an integrated medicine approach in relation to TCM makes it difficult to demonstrate the value of the contribution TCM can make to biomedicine in the field of breast care oncology. Effectiveness studies are needed that can accurately represent TCM in this field.
Source: Integrative Cancer Therapies - August 1, 2016 Category: Cancer & Oncology Authors: McPherson, L., Cochrane, S., Zhu, X. Tags: Articles Source Type: research